Sarepta Therapeutics (SRPT) PT Lowered to $187 at RBC Capital
RBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $187.00 (from $189.00) while maintaining a Outperform rating.
RBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $187.00 (from $189.00) while maintaining a Outperform rating.